Drug Discovery & Pharmaceuticals

RSS

Rice engineers use gene editing to facilitate drug discovery based on natural fungus

Rice University scientists have won federal support for their pursuit of novel drugs to treat human disease.

10 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

New process could fast track antiviral and anticancer drug discovery

Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from Simon Fraser University chemist Robert Britton and his international team.

7 Aug 2020

Chemists discover a way to create synthetic version of natural anti-cancer compound

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

6 Aug 2020

First DEA-registered hemp analytical testing lab in Texas

ZOSI Analytical, LLC, a hemp analytical testing laboratory in Central Texas, has announced it has received its Drug Enforcement Agency registration to handle Schedule 1 substances.

From ZOSI Analytical 6 Aug 2020

Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy

Yellow fever, an acute viral hemorrhagic disease transmitted by infected mosquitoes, infects about 200,000 people and causes an estimated 30,000 deaths each year.

5 Aug 2020

DSI introduces new, hands-on opportunity for drug sponsors to learn from CMC and regulatory subject matter experts

Design Space InPharmatics, an Industry Leader in Regulatory Drug Development, today announced its latest innovative offering for emerging biotech drug sponsors.

From DSI, a PLG Company 4 Aug 2020

Researchers develop scalable strategy to find novel molecular glue degraders

Despite enormous efforts to advance traditional pharmacology approaches, more than three quarters of all human proteins remain beyond the reach of therapeutic development.

4 Aug 2020

Touchlight, Cancer Research UK and University of Southampton team up to develop DNA cancer vaccine

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma.

31 Jul 2020

Waterloo tech profiles antibodies in blood of COVID-19 patients

A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses like cancer and COVID-19, is expanding operations with the help of a $5-million USD investment.

29 Jul 2020

Investigational drug for Alzheimer's disease may help autistic children

An extensive international study led by Prof. Illana Gozes of Tel Aviv University's Department of Human Molecular Genetics and Biochemistry found deposits of the tau protein typically found in Alzheimer's patients in tissues taken from the postmortem brain of a 7-year-old autistic child.

28 Jul 2020

Low-cost, environmentally-friendly hand sanitizer produced from plant and paper waste

A Tel Aviv University breakthrough allows, for the first time, a local production of ethanol -- and hand sanitizer -- based on plant and paper waste, using a novel lignin (a substance found in plants) degradation process.

27 Jul 2020

Arctoris supports global research efforts to combat COVID-19

Arctoris Ltd. supports global research efforts to find new therapeutics against COVID-19.

24 Jul 2020

Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Biognosys announced today that it started working together with Boehringer Ingelheim.

From Biognosys 24 Jul 2020

Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence

Ultivue and OracleBio partner to help further insights and advance personalized tumor characterization in translational and clinical oncology research.

From Ultivue 23 Jul 2020

Findings could help design vaccines against coronavirus

Scientists investigating the evolution of the virus that causes Covid19 say that its mutation seems to be directed by human proteins that degrade it, but natural selection of the virus enables it to bounce back. The findings could help in the design of vaccines against the virus.

23 Jul 2020

Erectile dysfunction drugs lower the accumulation of toxic proteins in zebrafish models

The aberrant buildup of misfolded proteins is a hallmark of a host of disorders, including neurodegenerative diseases such as Alzheimer's and Parkinson's.

22 Jul 2020

Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies

Thermo Fisher Scientific Inc., the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally.

From Thermo Fisher Scientific Inc. 22 Jul 2020

High-quality lab procedures crucial to discovery of effective drugs

In their quest to find new drugs to treat deadly diseases, scientists study millions of molecules at high speed at the same time. Often it is enzymes that are investigated as targets in these 'high-throughput' screenings.

21 Jul 2020

Drug discovery pipeline to exploit transcription factors for cancer therapy

Cancer is a leading cause of death and one of the most complex challenges to modern medicine. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up company QUANTRO Therapeutics strives to radically change the precision and scope of cell-based drug screening.